These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9934549)

  • 1. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.
    Doern GV; Pfaller MA; Erwin ME; Brueggemann AB; Jones RN
    Diagn Microbiol Infect Dis; 1998 Dec; 32(4):313-6. PubMed ID: 9934549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).
    Odland BA; Jones RN; Verhoef J; Fluit A; Beach ML
    Diagn Microbiol Infect Dis; 1999 Aug; 34(4):315-20. PubMed ID: 10459483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
    Bell JM; Turnidge JD; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
    Jones RN; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.
    Piddock LJ; Johnson M; Ricci V; Hill SL
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2956-60. PubMed ID: 9797232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
    Jones ME; Staples AM; Critchley I; Thornsberry C; Heinze P; Engler HD; Sahm DF
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2645-52. PubMed ID: 10991838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against streptococcus pneumoniae and enterococci isolates from the western hemisphere: example of international surveillance (SENTRY antimicrobial surveillance program )in the development of new drugs.
    Lewis MT; Jones RN
    Braz J Infect Dis; 2000 Feb; 4(1):15-21. PubMed ID: 10788841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
    Zhanel GG; Palatnick L; Nichol KA; Bellyou T; Low DE; Hoban DJ
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1867-74. PubMed ID: 12760860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
    J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
    Hoban DJ; Bouchillon SK; Karlowsky JA; Johnson JL; Butler DL; Miller LA; Poupard JA
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.
    Ho PL; Yung RW; Tsang DN; Que TL; Ho M; Seto WH; Ng TK; Yam WC; Ng WW
    J Antimicrob Chemother; 2001 Nov; 48(5):659-65. PubMed ID: 11679555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A; Sader H; Jones RN;
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.